durvalumab,oleclumab
astrazeneca
['synergy', 'durva', 'oleclumab', 'biomarker', 'marker ']
#esmo22 synergy trial in triple neg adenosine immunosuppressive, oleclumab blocks cd73 - stops adenosine accumulation carbo/taxol/durvalumab +/- oleclumab 1/2 pdl1+, 1/3 cd73+ sadly no differences found, no useful biomarker 
Medical oncologist from Perth - Australia. Interested in thoracic oncology, breast cancer, GUs, clinical trials, fast cars (Formula 1) and @werderbremen_en